Physician profile
John B Forward
NPI 1477507192
$8,019.47
in general payments reported to CMS, 2019-2025
29 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $869 · 2021: $778 · 2022: $1,215 · 2023: $1,029 · 2024: $1,292 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837 · Education: $30.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,837.22 |
| Education | $30.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,871.90 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,699.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $568.01 | 2024-2025 | Korlym |
| Lilly USA, LLC | $460.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $452.46 | 2021-2025 | |
| Amarin Pharma, INC. | $322.37 | 2019-2022 | |
| Amgen INC. | $301.21 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.39 | 2019-2025 | Jardiance |
| Pfizer INC. | $263.06 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $241.57 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $241.25 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $217.58 | 2021-2023 | |
| Allergan, INC. | $162.67 | 2019-2020 | |
| Exact Sciences Corporation | $149.07 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $111.59 | 2021-2025 | Aplenzin, Wellbutrin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $97.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $82.11 | 2023-2024 | Rexulti |
| Abbvie INC. | $76.58 | 2019-2025 | |
| Axsome Therapeutics, INC. | $68.59 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $56.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.91 | 2019 | |
| Vivus LLC | $29.12 | 2019 | |
| Astellas Pharma US INC | $27.94 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $27.79 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.76 | 2025 | Xifaxan |
| Vertical Pharmaceuticals, LLC | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Forward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.